The regeneration of large bone defects remains clinically challenging. The aim of our study was to use a rat model to use nasal chondrocytes to engineer a hypertrophic cartilage tissue which could be remodelled into bone in vivo by endochondral ossification.
Introduction
Bone is the second most transplanted tissue after blood. Despite this, the repair of large bone defects, whether congenital in nature or caused by trauma or disease remains clinically challenging. [1] Crucially, survival of transplanted bone tissue into a bone defect is dependent on the tissue receiving adequate blood supply to supply essential oxygen and nutrients and removal of waste products. Currently, autologous bone is the clinical 'gold standard' for bone tissue transplantation. Autologous bone is a living tissue with osteoconductive and osteoinductive properties which will not be rejected by the patient's immune system. There are, however, drawbacks to using autologous bone tissue including lasting post-operative pain from the donor site and donor site morbidity. [2] There are also limitations in the amount of healthy tissue that can be taken from a patient without causing instability in the remaining bone structures, an issue particularly pertinent in children. [2] Bone allografts and xenografts are used for bone repair, but these have to be decellularised to reduce their immunogenicity and as a consequence, are osteoconductive but have little osteoinductive capacity. Similarly, to date, current biomaterial bone graft substitutes have good osteoconductive properties but their osteoinductive properties are limited. Therefore, there is a strong clinical need to develop new bone graft materials for the repair and Most tissue engineering approaches have focussed on producing bone tissue by the route of intramembranous ossification in which mesenchymal stem cells are differentiated directly into osteoblastic cells to produce a bone-like extracellular matrix directly. One of the main challenges of bone tissue engineering by this route is the provision of a sufficient supply of nutrients and oxygen essential for the survival of the osteoblastic cells. During the culture of large three-dimensional tissue constructs, limited diffusion can cause problems in cell proliferation, differentiation and cell survival. Approaches to overcome these limitations include use of bioreactors [3, 4] to provide dynamic culture conditions and engineering prevascularised grafts by including endothelial cells with differentiation signals to stimulate formation of blood capillaries [5] .
Developmental tissue engineering, mimicking the natural pathways of tissue formation in body is a potential route to producing graft tissues for transplantation. Endochondral ossification is responsible for the formation of the axial skeleton and long bones [6] during embryogenesis and, is a potential and as of yet largely unexplored pathway of producing a suitable, alternative graft material for bone repair. Endochondral ossification involves the formation of a hypertrophic cartilage template which undergoes mineralisation, invasion by blood vessels and subsequent remodelling into bone. Hypertrophic cartilage formation and its remodelling into bone by endochondral ossification can be seen in the growth plate of young children and adolescents during periods of active growth and in the adult during healing of bone fractures where the 'soft' cartilage callus undergoes ossification into woven bone. In the growth plate, proliferative columnar chondrocytes produce a complex hyaline-cartilage extracellular matrix (ECM), in which the predominant protein is collagen type II. These M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 6 chondrocytes then undergo terminal differentiation to the hypertrophic chondrocyte phenotype and produce collagen type X in the ECM which is essential for mineralisation [7, 8] .
Cartilage constructs have several advantages over the more extensively researched bone tissue constructs formed by intramembranous ossification. Cartilage can withstand lower oxygen concentrations than bone tissue containing osteoblasts and mesenchymal stem cells [9] . This advantage of cartilage allows for both the culture of larger grafts, as well as enabling better survival of the cartilage graft once implanted at the site of injury. Hypertrophic cartilage also contains the required biological factors to promote matrix remodelling [10] , angiogenesis [11, 12] , and bone formation [13] , within the tissue. Therefore, once implanted in vivo, hypertrophic cartilage should recruit blood vessels and be remodelled into bone tissue via the normal physiological process of endochondral ossification. Hence, the potential of utilising tissue engineered hypertrophic cartilage warrants further research.
There has been widespread interest in the use of mesenchymal stem cells in regenerative medicine and tissue engineering for repair/regeneration of hyaline cartilage defects in the body; for example regeneration of articular cartilage in joints [14, 15] and cartilage defects in the head and neck area [16] for example, the nasal septum [17, 18] . In comparison, there has been little research focussed on engineering hypertrophic cartilage. Scotti et al demonstrated that bone marrow mesenchymal stem cells (BM-MSCs) in pellet culture were able to differentiate into hypertrophic-like chondrocytes which expressed both collagen type X and alkaline phosphatase and mineralised on subcutaneous implantation [7] . Scotti et al also reported that seeding BM-MSCs on a shaped collagen scaffold followed by chondrogenic priming formed a mineralised trabecular-like bone on subcutaneous implantation [19] . Sheehy et al [20] have also recently reported that BM-MSCs encapsulated in a shaped M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 7 hydrogel structure formed layer of mineralised tissue in the periphery of the constructs after in vitro chondrogenic priming followed by 8weeks of subcutaneous implantation. While mesenchymal stem cells have been approved for clinical use [21] other adult cells may offer an advantageous source for the production of a hypertrophic cartilage. Mesenchymal stem cells have been shown to produce cartilage with lower levels of ECM and reduced mechanical strengths when compared to adult chondrocytes [22, 23] . Primary adult hyaline chondrocytes, however, have been shown to produce high levels of GAG in the ECM when cultured in vitro, for the production of hyaline cartilage [22, 24] .
In terms of using chondrocytes to form hypertrophic cartilage, previous research has shown that immortalised adult articular chondrocytes become hypertrophic and mineralised in pellet culture [25] . Also, immortalised chondrocytes derived human embryonic femurs were reported to produce osteoinductive signals in the culture medium [26] . There are, however, significant regulatory and safety concerns associated with the use of genetically modified cells for clinical applications. Two sources of adult chondrocytes, nasal septum and rib cartilage, have potential as sources of adult hyaline chondrocytes which can undergo terminal differentiation to the hypertrophic phenotype. Both tissues have capacity in vivo for the cartilage to undergo endochondral ossification; for example, where the nasal cartilage is attached to the facial bone. Also, both tissues can be harvested clinically by biopsy. The nasal septum is potentially a simpler biopsy procedure with a lower risk of donor site morbidity. In addition, chondrocytes extracted from the nasal septum have been broadly studied in tissue engineering for their capacity to produce a hyaline cartilage matrix [24, [27] [28] [29] and have been used clinically for repair of septal defects [17] . Only one detailed in vivo study to date has considered the use of nasal chondrocytes for tissue engineering a hypertrophic cartilage template for bone regeneration [30] . Here engineered constructs did not mineralise following M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 8 sub-cutaneous implantation, but were capable of some mineralisation following osteogenic pre-culture and implantation within ceramic scaffolds. More recently, a population of nasoseptal chondrocytes with progenitor features were described by Rotter and co-workers [31] .
The overall aim of this study was to investigate whether chondrocytes isolated from the nasal septum, a potentially clinically relevant cell source, could produce a hypertrophic cartilage tissue which would remodel into bone on transplantation into a bone defect in vivo. Our first objective was to use a rat model in which to isolate and culture nasal chondrocytes and investigate whether the chondrocytes would produce a hypertrophic cartilage matrix in 3D culture using a poly-L-glycolic acid (PGA) scaffold support. Chondrocytes were also isolated from the rib and cultured in the same way as a comparator. The second objective was to implant the engineered hypertrophic cartilage subcutaneously in vivo to investigate biocompatibility, and angiogenesis in the implant. The engineered hypertrophic cartilage was also implanted in an in vivo bone defect in the calvaria of the rat to determine whether the cartilage would undergo remodelling into bone. 
Cell Isolation and Expansion
Nasal and rib cartilages were harvested from 6 week old Wistar rats within 2 hours of euthanasia and the chondrocytes isolated and cultured as we have described previously [32, 33] and is a similar method of cell isolation and expansion as reported by other researchers [24, 29, 31,] Briefly the cartilages were removed, washed in phosphate buffered saline (PBS) and any epithelial tissue removed by scraping the cartilage surfaces with a scalpel blade. The cartilages were again washed with PBS, cut into small pieces and incubated in 2.5% trypsin (Sigma Aldrich, UK) for 30 minutes followed by an overnight digestion in 3 mg.ml -1 bacterial collagenase Sigma Aldrich, UK) in basic medium [Dulbecco's modified eagle medium (DMEM) (Sigma Aldrich, UK) supplemented with non-essential amino acids (NEAA) (Sigma Aldrich, UK), 100 units.ml -1 penicillin and 100 ug.ml -1 streptomycin (Sigma Aldrich, UK), and 10 mM HEPES buffer (Sigma Aldrich, UK) and 10 % foetal calf serum (FCS, Biosera, UK)]. The chondrocytes were isolated from the digested tissue by passing the digested tissue through a 70 µm cell strainer (BD Biosciences, UK) followed by centrifugation (10 min, 192g) to pellet the cells. The cell pellet was washed to remove by suspending the cells in PBS and repeating the centrifugation step. This washing step was repeated once more and the final cell pellet suspended in basic culture medium containing 10 ng.ml -1 of fibroblast growth factor-2 (FGF-2, Peprotech, UK). The cells were plated into culture flasks and cultured in an incubator at 37 o C a humidified atmosphere of 5% CO 2 and 95% air. The culture media (basic medium containg10 ng.ml -1 FGF-2) was changed twice per week.
Scaffold
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A C C E P T E D ACCEPTED MANUSCRIPT 10 A commercial PGA scaffold (Biofelt ® , Cellon S.A., Luxembourg) was used. The Biofelt ® scaffold was a biodegradable, 1 mm thick, non-woven PGA felt with a bulk density of 70mg.cc -1 and was fabricated from medical grade polymer. For experiments, 5 mm diameter discs were cut from the scaffold sheet using a cork borer and the discs were covered with isopropanol for 15 min. to sterilise them, a method recommended by the manufacturer. The isopropanol was removed and the discs washed extensively with sterile PBS to ensure removal of the isopropanol. The scaffold discs were then conditioned in basic media for a further 20 minutes. This scaffold has been reported extensively, primarily as a reference material in investigations of novel biomaterials [34] [35] [36] .
Scaffold Seeding and 3D Culture
At passage 2, 2x10 6 cells were seeded per PGA scaffold for 72 hours in basic medium on an orbital shaker set at 35 revolutions per minute (rpm). The seeded constructs were removed and placed in fresh culture medium and then cultured for 42 days in basic medium containing 1 µg.ml -1 insulin and 50 µg.ml -1 ascorbic acid, to induce chondrocyte differentiation and extracellular matrix formation. After culture, the constructs were removed from the culture wells, lightly blotted with tissue to remove excess medium and weighed. The constructs were bisected perpendicularly and for each construct, one half was frozen at -20 o C for analysis of GAG content and the remaining half was mounted in Optimal Cutting Temperature (OCT) cyromountant and stored at -20 ºC for histology and immunohistochemistry. latex, Sigma Aldrich UK) After digestion, the samples were centrifuged at 10,000g to pellet remains of the PGA scaffold and the supernatant fraction was removed and stored at -20 o C until assay for glycosaminoglycan (GAG) content, The GAG concentration of the digested samples was determined using 1,9-dimethylmethylene blue (DMB) following the protocol described by Farndale et al. [37] . 
Glycosaminoglycan assay
Histology
Immunohistochemistry
Immunohistochemistry was used to assess collagen type II and X deposition throughout the constructs. Collagen expression was investigated using commercial antibodies: goat anti- 
Real Time RT-PCR (q-PCR)
After culture, the constructs were washed in PBS and flash frozen in liquid nitrogen for 30 seconds. A tissue pulveriser was used for 1 minute to homogenise the sample in PBS and the samples centrifuged at 11,000 rpm for 2 minutes. RNA was extracted immediately from the tissue pellet using a Bioline Isolate II RNA Mini Kit (Bioline Reagents Ltd, UK) and the concentration determined using a Nanodrop 2000. cDNA was synthesised using a high capacity RNA to cDNA master mix (Life Technologies, UK) and 100 ng of RNA per reaction. Reactions were run in a thermal cycler using a cycle of 10 minutes at 25 °C, 2 hours at 37 °C, 5 minutes at 85 °C and then 10 minutes at 4 °C. Results were analysed using the ∆∆ct method in relation to the housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (4352338E) expression. The ∆∆ct value was then normalised to undifferentiated 3D culture chondrocytes, to assess the differentiation on the PGA scaffold material.
In vivo Experiments
Subcutaneous implantation of constructs.
Rat nasal chondrocytes were cultured on PGA scaffolds under standard conditions as Rats were anaesthetised using IsoFlo (Isofluorane, Abbott Laboratories, UK) and given antibiotics, Synulox (Pfizer, UK), and a painkiller, Metacam (Boehringer-Ingleheim, Germany). The anesthetised animals were weighed and a midline incision was made in the skin covering the skull and both the skin and periosteum were retracted to reveal the cranium. Two 4 mm full thickness defects were drilled into the skull using a 3.5 mm diamond burr with saline irrigation. The constructs Grafts were cut to 4 mm diameter using a sterile biopsy punch and placed into one of the defects with the other being left empty. The periosteum was closed over the defects and secured with 2 vicryl stitches, before the wound was closed using 4-5 stitches.
Constructs were left in the cranial defects for 4, 8 or 12 weeks, before the animals were culled. Rats were anesthetised using IsoFlo and their vertebrae separated, the heads were then removed from the animal and placed in 10 % (w/v) neutral buffered formalin. The cranial defects were then examined by microcomputed tomography (micro-CT) and histology to assess the degree of new bone formation in the defect area. After decalcification the craniums were dissected and embedded in paraffin wax for histological analysis.
Results
Analysis of Constructs
Sternal and nasal hyaline chondrocytes were compared for their ability to undergo hypertrophic differentiation on PGA scaffolds. Both sternal and nasal-derived chondrocytes seeded onto the scaffolds to a similar extent (over 90% seeding efficiency). The constructs were incubated for up to 42 days after which they were terminated and analysed as described in the methods. Deposition of proteoglycan, collagens II and X showed extensive distribution in constructs formed from either nasal or sternal chondrocytes by day 42 (Figure 1 ). An increase in cell volume was found in constructs from both chondrocyte types and collagen X deposition was observed in areas of chondrocytes showing increased cell volume. (Figure 1 
Effect of 3D Culture on Chondrocyte Gene Expression
After isolation from native cartilage, the nasal chondrocytes were grown in 2-dimensional (2D) monolayer culture to expand the numbers of cells. After culturing the chondrocytes on the PGA scaffold for 72 hours in basal media a distinct change in the gene expression was observed (Supplementary data, Figure 2 ) compared to the 2D monolayer cultures. Significant increases in the expression of Ihh, Sox9, and collagen type II were observed indicating the chondrocytes were reverting to a more hyaline phenotype. Conversely markers of hypertrophic differentiation, collagen type X, alkaline phosphatase and Runx2, were significantly decreased during the first 72h of culturing the chondrocytes were in the 3D environment of the PGA scaffolds.
Effect of Differentiation on Chondrocyte Gene Expression
Gene expression within the cartilage constructs changed significantly throughout the 42-day culture period following the scaffold seeding period (Figure 3) . The ECM component, collagen II, a marker of a hyaline chondrocyte phenotype, continued to increase after the initial 72 hour cell-seeding period, until day 7 where a 6-fold increase in gene expression was observed. After day 7, the gene expression of collagen II was significantly downregulated throughout the remainder of the culture period (Figure 3a) . Conversely, gene expression for collagen X increased from day 7 to day 14 with a reproducible decease in expression at day 21 followed by increase expression to reach a peak of 100-fold increase at (Figure 3b) . Similarly, gene expression for alkaline phosphatase increased from day 7 to peak levels by days 35 (Figure 3c ). The gene expression of the signalling protein, Indian hedgehog (IHH), a pre-hypertrophic marker, rose from day 14 with a significant peak in expression by day 21 (30-fold increase) before falling to lower levels (6 fold) (Figure3d).
Gene expression of the transcription factor Sox9 was significantly reduced at day 3 until day 35 when there was an increase in expression corresponding with the timing of peaks in collagen type X and alkaline phosphatase gene expression ( Figure 3e ). Expression of the transcription factor, Runx2 was increased by day 14 of the culture period and reached a peak 
In Vivo Repair
Subcutaneous implantation
Since the hypertrophic constructs failed to mineralise in vitro; subcutaneous implantation of the hypertrophic constructs was carried out to determine if the constructs would undergo mineralisation in vivo. Before implantation, the constructs showed features of hypertrophic cartilage tissue shown by areas of hypertrophic cells; some areas of collagen X deposition in the ECM and alkaline phosphatase enzyme activity (refer to Supplementary Figure 3 ).
Histological analysis of the retrieved constructs revealed that they were encapsulated by a thin layer of fibrous, connective tissue. Immunolocalisation studies, using anti-CD45+ to detect leukocytes and anti-CD68+ antibodies to detect macrophages, showed some inflammatory cells were present around the outer areas of the retrieved constructs but their localisation was sparse and was restricted mostly to non-cartilage areas ( Supplementary   Figure 4) . No giant cells were detected.
Numerous blood vessels were present on the surface of implants and throughout their interior after 4 weeks of implantation (Figure 4b Figure   4g ). After 4 weeks of implantation collagen X was distributed throughout the cartilaginous areas of constructs (Figure 4a, b) . Additionally, alkaline phosphatase was detected in the implanted constructs (Figure 4c, d) . In contrast to the in vitro experiments, after 4 weeks of implantation calcium deposition was observed in all the samples (Figure 4e In contrast, no mineralisation was observed in the constructs which were maintained in in vitro culture for an additional period of 4 weeks (Supplementary Figure 5 ) although extensive deposition of collagen X and alkaline phosphatase activity was observed during the extended culture period.
Cranial implantation
The pre-implantation constructs after 35 days of differentiation showed a hypertrophic phenotype in terms of large cell size, collagen X and alkaline phosphatase expression ( Supplementary Figure 6 ).
In the absence of cells and some ECM formation, PGA has a very rapid rate of dissolution releasing acidic degradation products which had the possibility of causing an inflammatory reaction in a relatively confined area close to the surface of the brain [39] . Therefore, a cellfree PGA scaffold could not be implanted into the empty defect. Implantation of a tissue engineered hypertrophic cartilage graft promoted bone mineralised formation at all time points examined (Figures 5a, 5b, 5c ). (Figures 5b and 5d ). This is also supported by the morphological appearance of the bone-like tissue which has formed within the defect when analysed histologically (Figure 5 a, b) . By week 12, micro-CT data showed that 38.48 % of the defect was mineralised (Figures 5c, d) compared to the untreated defect (7.56%) and further remodelling of the hypertrophic cartilage into bone was also observed histologically.
Little bone formation was observed within the calvarial defects which had remained empty (i.e. they had not received a hypertrophic cartilage construct). In these a fibrous tissue had formed bridging the defect ( Supplementary Figure 7) . 
Discussion
This is a proof of concept study using a rat model which shows the use of nasal chondrocytes to produce a tissue engineered hypertrophic construct in vitro. This study has demonstrated that this engineered hypertrophic cartilage material has the ability to undergo ossification and enhance bone regeneration in a bone defect in vivo. Non-woven PGA was chosen as a scaffold material as these polyesters have been well researched for tissue-engineering as they have Food and Drug Administration approval for clinical use [38] . PGA has the disadvantage of releasing glycolic acid by-products during degradation, and has been reported to induce inflammation and necrosis of nearby tissues [39] . Use of a PGA scaffold allowed for good cell attachment, proliferation and hypertrophic differentiation. On subcutaneous implantation of the hypertrophic constructs, a mild inflammatory response was observed on the periphery of the construct indicated by immunolocalisation of macrophages (CD 45+ cells) and lymphocytes (CD68+cells). No obvious inflammation was observed on implantation of the hypertrophic constructs into the cranial bone defect model.
The tissue engineered hypertrophic cartilage produced in this study was shown to have similar features to that seen in the growth plate. The engineered tissue exhibited a large cellular morphology and expressed the classical hypertrophic cartilage markers of collagen type X and alkaline phosphatase in the extracellular matrix. The temporal gene expression of Sox9, collagens II and X, Runx2 and alkaline phosphatase during the in vitro culture period in the nasal chondrocyte/PGA constructs also reflected that observed during chondrocyte hypertrophy within the growth plate [41] . Chondrocytes are well known to dedifferentiate during 2D culture conditions which are used to expand the numbers of cells for seeding onto scaffolds [40] . During 3D culture, the gene expression of collagen II was elevated by day 7 and indicative of the chondrocytes regaining a hyaline chondrogenic phenotype. By day 14
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A C C E P T E D ACCEPTED MANUSCRIPT 27 the collagen II gene expression was significantly down regulated and collagen X expression increased with alkaline phosphatase gene expression from day 7 of the culture reaching a peak at day 35 of culture. The temporal gene expression of signalling molecule, IHH, and transcription factors, Sox9 and Runx2 were also monitored throughout the differentiation period and found to reflect that reported for chondrocyte hypertrophy in the growth plate.
In the growth plate, IHH expression is localised to the area of post-mitotic, pre-hypertrophic chondrocytes which is adjacent to the proliferating columnar cells and regulates hypertrophic differentiation of chondrocytes [42] . IHH is reported to work through two mechanisms, inhibiting hypertrophic differentiation through the PTHrP pathway and Ptc-1 receptor or promoting hypertrophic differentiation through the Wnt/BMP pathway [42] [43] [44] [45] . A peak of IHH gene expression was observed at day 21 just before a peak of Runx2 expression. Runx2 is essential during hypertrophic differentiation as it is known to regulate the expression of other genes associated with mineralisation and angiogenesis, including BMPs and VEGF to induce angiogenesis in the cartilage. Runx2 also promotes the extracellular matrix remodelling via synthesis of matrix metalloproteinases (MMPs) and osteopontin which enables osteoclast attachment [48] [49] [50] [51] [52] . These downstream proteins are essential for the subsequent mineralisation and bone formation within the tissue-engineered hypertrophic cartilage. Sox9 is believed to work via the PTHrP pathway to maintain cells in a proliferative state. [46] . Dy et al, however, have shown that Sox9 is also an important transcription factor for hypertrophic differentiation, where it is located to the nuclei of chondrocytes where it acts upon the collagen type X promoter both independently and through cooperation with mef2c [47] . We observed downregulation of Sox9 throughout the culture period with increased Sox9 expression on day 35 which corresponded to the peak expression of collagen type X within the constructs.
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This ability to create an engineered tissue with the morphological and phenotypical feature of natural hypertrophic cartilage is essential to allow of mineralisation and bone remodelling in vivo. While the production of an engineered tissue with characteristics of hypertrophic cartilage was successful in vitro on the PGA scaffold material, these constructs failed to show cartilage mineralisation in vitro. However, the constructs did undergo cartilage mineralisation on in vivo implantation (Figure 4 ) but not on extended in vitro culture. Mineralisation of hypertrophic cartilage is a prerequisite step for the later ossification. There are several hypotheses as to why cartilage mineralisation did not occur in vitro. Either the culture conditions used were not conducive to cartilage mineralisation by the hypertrophic chondrocytes or that the interaction of another cell type, for example, endothelial or osteoblast progenitors, was required in order for initiation of the cartilage mineralisation stage.
On in vivo subcutaneous implantation vascularisation of the tissue constructs occurred before subsequent mineralisation and bone formation was observed. Endothelial progenitors and haematopoietic stem cells which express CD34 + have previously been shown to be important for the neovascularisation of fractures and subsequent fracture healing [53] . Olmsted-Davis et al observed that CD34+ cells have the ability to generate osteogenic cells, which can express osteogenic markers, osteocalcin and alkaline phosphatase [54] . The decrease in ECM observed around the vascularisation of the graft can be attributed to the vascularisation of the hypertrophic cartilage. MMPs have been shown to be expressed by and around areas of vascularisation, including MMP-9 (gelatinase B) which has been shown to degrade collagens within the ECM of hypertrophic cartilage [55]. This need for the initial vascularisation of the tissue constructs highlights the importance of the expression of angiogenic factors, such as VEGF, within the grafts in order to recruit the CD34+ cells [11] .
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A C C E P T E D ACCEPTED MANUSCRIPT 29 On implantation into a cranial bone defect, the nasal chondrocyte/PGA constructs were invaded by blood vessels and the cartilage was re-modelled into bone-like tissue. Although the size of bone defect used enabled self-healing given sufficient time; the bone defects containing the nasal chondrocyte/PGA constructs showed significantly more bone regeneration. The bone regeneration observed within the hypertrophic cartilage grafts after in vivo implantation therefore may be a downstream reaction to the invasion of the tissue by blood vessels and the degradation of the hypertrophic cartilage matrix, as vascularisation allows for the influx of osteoblasts and monocyte-derived osteoclasts to regulate bone formation [12] .
Conclusion
There are relatively few studies looking at the potential of using hypertrohic cartilage as a potential method to produce a bone graft substitute and most of this research is directed to using bone marrow derived MSCs to engineer cartilage constructs with hypertrophic cartilage features. This study shows that that adult nasal chondrocytes can be used to produce a tissue 
